Coeptis Therapeutics Inc Stock Price, News & Analysis

Coeptis (Nasdaq: COEP) has announced a strategic partnership between its NexGenAI Affiliates Network and MarketLeverage, combining AI technology with performance-based marketing strategies. The collaboration provides access to MarketLeverage's network of 5,500 advertisers and 55,000 publishers, creating one of the industry's most extensive affiliate networks.

The partnership integrates AI-driven campaign management, predictive analytics, and automated outreach capabilities. Affiliates will earn commissions through automated content distribution, social media sharing, and targeted email campaigns, with AI optimizing performance in real-time.

The artificial intelligence marketing market is projected to grow from $27.83 billion in 2024 to $106.54 billion in 2029, with a CAGR of 31.6%.

COEPTIS (Nasdaq: COEP) has announced the launch of COEP Venture Group, a new investment arm focused on funding startups specializing in Artificial Intelligence, Robotic Process Automation, and AI Agents. The venture group will be led by Michael Woloshin, co-founder of Recruiter.com and founder of NexGenAI Solutions Group.

The investment focus includes advanced machine learning models, AI-powered automation for workflow optimization, autonomous AI-powered assistants, and emerging technologies like blockchain applications. COEP Venture Group will provide capital, strategic mentorship, and industry network access to portfolio companies, while leveraging NexGenAI Solutions Group to provide marketing services.

This initiative expands COEPTIS's existing portfolio, which includes biopharmaceutical divisions focusing on cell therapy platforms for cancer, autoimmune, and infectious diseases, featuring assets licensed from Deverra Therapeutics and partnerships with VyGen-Bio and the Karolinska Institute.

COEPTIS (NASDAQ: COEP) has successfully completed its Series A Preferred financing round, raising an additional $5.7 million for a total of $10 million. The latest funding was led by CJC Investment Trust, controlled by board member Christopher Calise. The Series A Preferred is convertible to common stock at $8.00 per share, with investors receiving a 15% equity stake in two newly formed subsidiaries: SNAP Biosciences and GEAR Therapeutics.

The financing follows an initial closure of $4.3 million in June 2024. Funds will be used to strengthen the company's balance sheet, repay obligations, and support general corporate purposes. Notably, the capital will accelerate COEPTIS' integration of AI solutions and automation capabilities, particularly through their recently acquired NexGenAI Affiliates Network platform, aimed at enhancing research processes and operational efficiency in the biopharmaceutical sector.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced its rebranding to COEPTIS, signaling a strategic expansion beyond biopharmaceuticals into technology-driven sectors. The company has established a new Technology Division, marked by the acquisition of the NexGenAI Affiliates Network platform, an AI-powered marketing solution.

The transformation aims to enhance operational capabilities and maximize shareholder value through technology integration. The NexGenAI platform will provide AI-driven marketing solutions for highly regulated industries, while the Technology Division focuses on developing automation capabilities and AI agents to optimize workflows.

According to CEO Dave Mehalick, this strategic shift aims to create revenue-generating, cash flow-positive business units, positioning COEPTIS as a self-sustaining entity. The company's technology suite includes AI-driven marketing software, robotic process automation (RPA), and data analytics tools designed to enhance communication strategies and drive sustainable growth.

Coeptis Therapeutics Holdings (Nasdaq: COEP), a biopharmaceutical company specializing in cell therapy platforms, has announced the expansion of its technological initiatives to include artificial intelligence and blockchain solutions. Following the successful launch of its Technology Division, the company aims to enhance operational efficiency and customer engagement through these advanced technologies.

CEO Dave Mehalick expressed enthusiasm about building upon the momentum generated by their Technology Division, particularly in AI, while exploring blockchain opportunities. The company views this expansion as a strategic move to remain at the forefront of technological developments and adapt to the evolving digital marketplace.

Coeptis Therapeutics Holdings (Nasdaq: COEP) announced it has regained compliance with Nasdaq's Listing Rule 5550(a)(2), known as the 'Bid Price Rule', following the Nasdaq Hearings Panel's decision from September 17, 2024. This development represents a positive start for the biopharmaceutical company, which focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the initial rollout of its NexGenAI Affiliates Network platform, securing five new customers with a total contract value of $1.7 million. The company has signed multiple Managed Services Agreements valued at $1.25 million with an anticipated recurring monthly revenue stream of $450,000.

The NexGenAI platform integrates AI-driven marketing software, robotic process automation (RPA), and data analytics to optimize campaigns and streamline operations. The platform features include AI Dialer Service, AI SMS Service, and RPA Assistance for marketing, recruitment, investment, and affiliate services.

CEO Dave Mehalick expressed optimism about the platform's early adoption and outlined plans for rapid rollout throughout 2025. The company expects significant growth through additional contracts with prospective clients currently under discussion.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced a 1-for-20 reverse stock split effective December 31, 2024. Upon implementation, every 20 shares of outstanding common stock will be converted into one share, with fractional shares rounded up to the next whole number. The reverse split aims to help the company meet Nasdaq Capital Market's minimum bid price requirement of $1.00 per share.

The split was approved by stockholders on December 18, 2024, and will not alter stockholders' percentage interest in the company's outstanding common stock, except for adjustments from fractional share treatment. Continental Stock Transfer is serving as the exchange agent, with stockholders holding shares in brokerage accounts not required to take any action.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the acquisition of the NexGenAI Affiliates Network platform and launched Coeptis Technologies, marking a strategic expansion into AI-powered solutions. The platform, developed by NexGenAI Solutions Group, provides AI-powered marketing software and robotic process automation (RPA) capabilities designed for the biotech, pharmaceutical, and multi-level marketing industries.

The acquisition aims to enhance marketing optimization, customer engagement, and operational efficiency in highly regulated sectors. The company views this integration as a strategic move to leverage advanced technologies within the biopharmaceutical sector and provide innovative tools for companies facing marketing challenges in competitive industries.